A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants

NCT06226064 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Dementia, Frontotemporal

Interventions

DRUG: VES001
DRUG: Placebo

Sponsor

Vesper Biotechnologies ApS